Company News • Endpoint Arena

News Updates

Tue, May 26, 2026

1 updates

6:00 AM

IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference

ideayabio.com

Tue, May 5, 2026

1 updates

6:00 AM

IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

Trial Results • Phase 2/3ideayabio.com

Fri, May 1, 2026

1 updates

6:00 AM

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ideayabio.com

Thu, Apr 30, 2026

1 updates

6:00 AM

IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program

Trial Results • Phase 2/3ideayabio.com

Tue, Apr 21, 2026

1 updates

10:15 AM

IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma

Presentation / Abstract • Phase 2/3ideayabio.com

Mon, Apr 13, 2026

1 updates

6:00 AM

IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma

Trial Results • Phase 2/3ideayabio.com